Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 12:12:52 03/06/2024 BST			5-day change	1st Jan Change
8.28 ^GBX	+5.75%		+6.29%	-70.43%

05-23	Celadon ships to US; Oxford BioDynamics-Goodbody pact	AN
05-23	Oxford Biodynamics plc Partners with the London Clinic to Offer EpiSwitch PSE and EpiSwitch CiRT Tests	CI

Oxford BioDynamics to provide tests to largest UK charitable hospital

May 21, 2024 at 02:09 pm

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

The partnership will see the Oxford, England-based biotech company provide the UK's largest independent charitable hospital with cancer detecting EpiSwitch blood testing products.

This agreement covers both the prostate screening and checkpoint inhibitor response tests.

Chief Executive Officer Jon Burrows said: "Through this new partnership with The London Clinic we are delivering potentially life-changing blood tests, which can safeguard the wellbeing of at-risk patients whilst reducing the cost of care."

This latest announcement follows October's deal with Bupa UK to provide coverage for the EpiSwitch CiRT test.

Oxford BioDynamics shares were up 4.2% to 7.92 pence each in London on Tuesday afternoon.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Oxford BioDynamics Plc

Celadon ships to US; Oxford BioDynamics-Goodbody pact	05-23	AN
Oxford Biodynamics plc Partners with the London Clinic to Offer EpiSwitch PSE and EpiSwitch CiRT Tests	05-23	CI
Oxford BioDynamics to provide tests to largest UK charitable hospital	05-21	AN
Oxford Biodynamics, London Clinic Sign Partnership Deal for Use of Blood Tests	05-21	MT
Bens Creek considers administration; Nexxen inks deal	05-16	AN
Oxford BioDynamics, plc and King's College London Collaborate on RA	05-16	CI
Oxford BioDynamics reaches "important milestone" with new laboratory	04-03	AN
Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test	04-03	CI
Oxford Biodynamics Raises GBP9.9 Million to Support EpiSwitch Product Line	03-14	MT
FireAngel CFO resigns; ECR Minerals raises GBP585,000	03-14	AN
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal	03-13	AN
Oxford BioDynamics plunges as annual loss widens; revenue up	01-17	AN
Oxford BioDynamics plunge as annual profit rises; revenue up	01-17	AN
Oxford BioDynamics shares plunge as annual revenue widens; revenue up	01-17	AN
AIM WINNERS & LOSERS: James Cropper falls on lower outlook	01-17	AN
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Revenue GBP510,000	01-17	MT
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Loss GBX-7.30	01-17	MT
Oxford BioDynamics Plc Reports Earnings Results for the Full Year Ended September 30, 2023	01-17	CI
Oxford BioDynamics Appoints Steven Arrivo as Senior Vice President of Business and Corporate Development	11-08	CI
FTSE 100 Edged Lower, Buoyed by Resilient Retail Sector	11-07	DJ
Oxford BioDynamics director sells over 700,000 shares	20/10/23	AN
Oxford BioDynamics Strikes Deal with Bupa for Access to Blood Test	18/10/23	MT
Oxford BioDynamics in deal with Bupa to expand blood test access	18/10/23	AN
Oxford BioDynamics, Plc Announces a Strategic Agreement to Give Bupa Patients Access to OBD'sEpiSwitch CiRT	18/10/23	CI
AIM WINNERS & LOSERS: Safestyle plunges as seeks cash injection	03/10/23	AN

Chart Oxford BioDynamics Plc

Duration

Period

More charts

Company Profile

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST, EpiSwitch PSE, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

Sector

Biotechnology & Medical Research

Calendar

18/06/2024 - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD BIODYNAMICS PLC	-70.43%	20.15M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.32%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research